CANF — Can Fite Biopharma Share News
0.000.00%
Last trade - 00:00- $4.92m
- $1.93m
- $0.41m
Can-Fite BioPharma up on positive data from psoriasis therapy study
Brief: Can-Fite Announces Positive Top-Line Results From Piclidenoson Phase Iii Comfort Study In Moderate To Severe Psoriasis
Brief: Can-Fite's CF602 Reverses Erectile Dysfunction In Diabetic Pre-Clinical Model Study Published In Peer-Reviewed Journal
Brief: Can-Fite Reports First Quarter 2022 Financial Results & Provides Clinical Update
Brief: Can-Fite Granted Key Nash Patent In Israel
Can-Fite up after topical psoriasis therapy shows promise in pre-clinical model
Brief: Can-Fite Developing Topical Piclidenoson Psoriasis Treatment That Shows Efficacy In A Preclinical Model
Brief: Can Fite Biopharma Ltd Says Namodenoson's Treatment Of Liver Fibrosis Receives Notice Of Allowance From U.S. Patent Office
Can-Fite Bio falls on delay in psoriasis therapy study data
Brief: Can-Fite’S Phase III Psoriasis Study Data Expected Q2 2022
Brief: Can Fite Announces First Patient Enrolled In Phase IIB Nash Clinical Trial With Namodenoson
Brief: Can-Fite To Conduct Investor Meetings During The J.P. Morgan Healthcare Conference
U.S. STOCKS ON THE MOVE-Calix, Codex DNA, Victoria's Secret
U.S. STOCKS ON THE MOVE-Rivian, Pop Culture Group, Can Fite Biopharma
Can Fite Biopharma to file patent applications after promising cancer drug data, shares rise
Brief: Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Various Advanced Solid Tumors
Brief: Can-Fite Announces Exercise Of Warrants For Cash Proceeds Of $10 Million
Brief: Can-Fite’s Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in Jan.; Topline Data Expected Q1 2022
Brief: Can-Fite Reports Third Quarter 2021 Financial Results & Provides Clinical Update